Beam Therapeutics (BEAM)
NASDAQ: BEAM · Biotechnology—Gene Editing · Cambridge, MA
Our rating: Cautious
Cautious reaffirmed at $29.07, moderate conviction, August 19, 2026.
Breaks if: The Cautious view would be proven wrong if Beam reports trailing annual revenue above $250 million with free cash flow burn narrowing below $200 million within the next four quarterly filings — conditions that would indicate the collaboration pipeline is converting at genuine scale and that cash consumption is moving toward a sustainable level. In price terms, a sustained move above $40 within twelve months, accompanied by a real improvement in the free cash flow profile, would constitute clear invalidation.
Key figures
| Market value | $2.2B |
|---|---|
| Revenue, last 12 months | $147M |
| Net income, last 12 months | −$108M |
| Free cash flow, last 12 months | −$398M |
| Price to earnings | n/a |
| Free cash flow yield | −18.4% |
| Dividend yield | 0.0% |
| Operating margin | −267.7% |
| Return on equity | −11.3% |
| Beta to the S&P 500 | 1.82 |
| Volatility, annualized | 72.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $307000.00 | −96.8% | $-1.28 | −$112M |
| June 30, 2026 | $490000.00 | −94.2% | $-1.18 | −$69M |
| March 31, 2026 | $32M | 324.9% | $-0.91 | −$131M |
| December 31, 2025 | $114M | 279.5% | $2.50 | −$87M |
| September 30, 2025 | $10M | −32.0% | $-1.10 | −$86M |
| June 30, 2025 | $8M | −28.1% | $-1.00 | −$80M |
| March 31, 2025 | $7M | 0.8% | $-1.23 | −$107M |
| December 31, 2024 | $30M | −90.5% | $-1.09 | −$79M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.23B: Claude 8%, Gemini 5%, Mistral 10%
- Diluted earnings per share are at least $2.50: Claude 7%, Gemini 5%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 10%, Gemini 5%, Mistral 2%
21 ledger entries and 20 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.